Attogene

Attogene

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2013, Attogene has established itself as a developer and manufacturer of diagnostic assays, primarily for environmental and food safety applications. The company's product portfolio includes kits for detecting cyanotoxins, shellfish poisons, pesticides, heavy metals, and viruses like COVID-19 and RSV. Operating as a private entity, Attogene generates revenue through direct kit sales, custom assay development services, and distribution of partner products, positioning itself at the intersection of biotechnology and environmental health.

Diagnostics

Technology Platform

Multi-format diagnostic platform specializing in Lateral Flow Assays (with Gold, Europium, Quantum Dot, Phycoerythrin labels), Enzyme-Linked Immunosorbent Assay (ELISA), and Polymerase Chain Reaction (PCR) for detection of environmental toxins, pathogens, and contaminants.

Opportunities

Growing regulatory and public focus on water quality and harmful algal blooms (HABs) creates a expanding market for its specialized cyanotoxin detection kits.
The demand for decentralized, rapid testing in food safety and environmental monitoring aligns perfectly with its lateral flow and portable assay expertise.

Risk Factors

Intense competition from larger, established diagnostics companies with greater sales and marketing resources.
Market dependence on environmental monitoring budgets, which can be cyclical and subject to government funding changes.

Competitive Landscape

Attogene competes in the broad field of life science tools and diagnostics, facing off against large players like Abcam, Thermo Fisher, and PerkinElmer in ELISA, and numerous companies in lateral flow. Its differentiation lies in its specific focus on environmental and algal toxin targets, its custom services, and its multi-label universal lateral flow platform.